Applications of oxetanes in drug discovery and medicinal chemistry

被引:16
作者
Huang, Guang [1 ]
Hucek, Devon [1 ]
Cierpicki, Tomasz [1 ]
Grembecka, Jolanta [1 ]
机构
[1] Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA
关键词
Oxetanes; Drug design; Drug discovery; Kinase; Enzyme; Inhibitors; BRUTONS TYROSINE KINASE; FATTY-ACID SYNTHASE; HOMOLOG; EZH2; SELECTIVE INHIBITOR; SERINE SYNTHESIS; RATIONAL DESIGN; C-THETA; POTENT; PROTEIN; CANCER;
D O I
10.1016/j.ejmech.2023.115802
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The compact and versatile oxetane motifs have gained significant attention in drug discovery and medicinal chemistry campaigns. This review presents an overview of the diverse applications of oxetanes in clinical and preclinical drug candidates targeting various human diseases, including cancer, viral infections, autoimmune disorders, neurodegenerative conditions, metabolic disorders, and others. Special attention is given to biologically active oxetane-containing compounds and their disease-related targets, such as kinases, epigenetic and nonepigenetic enzymes, and receptors. The review also details the effect of the oxetane motif on important properties, including aqueous solubility, lipophilicity, pKa, P-glycoprotein (P-gp) efflux, metabolic stability, conformational preferences, toxicity profiles (e.g., cytochrome P450 (CYP) suppression and human ether-a-go-go related gene (hERG) inhibition), pharmacokinetic (PK) properties, potency, and target selectivity. We anticipate that this work will provide valuable insights that can drive future discoveries of novel bioactive oxetanecontaining small molecules, enabling their effective application in combating a wide range of human diseases.
引用
收藏
页数:32
相关论文
共 160 条
[1]   An axonal stress response pathway: degenerative and regenerative signaling by DLK [J].
Adib, Elham Asghari ;
Smithson, Laura J. ;
Collins, Catherine A. .
CURRENT OPINION IN NEUROBIOLOGY, 2018, 53 :110-119
[2]   FKBP12, the 12-kDa FK506-binding protein, is a physiologic regulator of the cell cycle [J].
Aghdasi, B ;
Ye, KQ ;
Resnick, A ;
Huang, A ;
Ha, HC ;
Guo, X ;
Dawson, TM ;
Dawson, VL ;
Snyder, SH .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (05) :2425-2430
[3]   LRRK2 kinase in Parkinson's disease [J].
Alessi, Dario R. ;
Sammler, Esther .
SCIENCE, 2018, 360 (6384) :36-37
[4]   BTK inhibitors in the treatment of hematological malignancies and inflammatory diseases: mechanisms and clinical studies [J].
Alu, Aqu ;
Lei, Hong ;
Han, Xuejiao ;
Wei, Yuquan ;
Wei, Xiawei .
JOURNAL OF HEMATOLOGY & ONCOLOGY, 2022, 15 (01)
[5]   Chemical Space Exploration of Oxetanes [J].
Alves, Fernando Rodrigues de Sa ;
Counago, Rafael M. ;
Laufer, Stefan .
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (21) :1-18
[6]   Unusual Transformations of Strain-Heightened Oxetanes [J].
An, Jason ;
Riel, Louis P. ;
Howell, Amy R. .
ACCOUNTS OF CHEMICAL RESEARCH, 2021, 54 (20) :3850-3862
[7]   The development of inhibitors of leucine-rich repeat kinase 2 (LRRK2) as a therapeutic strategy for Parkinson's disease: the current state of play [J].
Azeggagh, Sonia ;
Berwick, Daniel C. .
BRITISH JOURNAL OF PHARMACOLOGY, 2022, 179 (08) :1478-1495
[8]  
Battles MB, 2016, NAT CHEM BIOL, V12, P87, DOI [10.1038/NCHEMBIO.1982, 10.1038/nchembio.1982]
[9]   Discovery of Lanraplenib (GS-9876): A Once-Daily Spleen Tyrosine Kinase Inhibitor for Autoimmune Diseases [J].
Blomgren, Peter ;
Chandrasekhar, Jayaraman ;
Di Paolo, Julie A. ;
Fung, Wanchi ;
Geng, Guoju ;
Ip, Carmen ;
Jones, Randall ;
Kropf, Jeffrey E. ;
Lansdon, Eric B. ;
Lee, Seung ;
Lo, Jennifer R. ;
Mitchell, Scott A. ;
Murray, Bernard ;
Pohlmeyer, Chris ;
Schmitt, Aaron ;
Suekawa-Pirrone, Kimberly ;
Wise, Sarah ;
Xiong, Jin-Ming ;
Xu, Jianjun ;
Yu, Helen ;
Zhao, Zhongdong ;
Currie, Kevin S. .
ACS MEDICINAL CHEMISTRY LETTERS, 2020, 11 (04) :506-513
[10]   The oxetane conformational lock of paclitaxel: Structural analysis of D-secopaclitaxel [J].
Boge, TC ;
Hepperle, M ;
Vander Velde, DG ;
Gunn, CW ;
Grunewald, GL ;
Georg, GI .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1999, 9 (20) :3041-3046